Related Experiment Video
Updated: May 13, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
PARP inhibition as a prototype for synthetic lethal screens
1Cancer Research, Abbott Laboratories, Abbott Park, IL, USA.
Abstract:
Although DNA damaging chemotherapy and radiation therapy remain the main stay of current treatments for cancer patient, these therapies usually have toxic side effect and narrow therapeutic window. One of the challenges in cancer drug discovery is how to identify drugs that selectively kill cancer cells while leaving the normal cell intact. Recently, synthetic lethality has been applied to cancer drug discovery in various settings, and has become a promising approach for identifying novel agents for the treatment of cancer. A prototypical example is the synthetic lethal interaction between PARP inhibition and BRCA deficiency. PARP inhibitors represent the most advanced clinical agents targeting specifically DNA repair mechanisms in cancer therapy. In this chapter, I will review the molecular mechanism for this synthetic lethality and the clinical applications for PARP inhibitors. I will also discuss the formats of synthetic lethal screens, current progress on the utilization of these screens, and some of the advantages and challenges of synthetic lethal screens in cancer drug discovery.
Insights
Synthetic lethality offers a promising strategy for cancer drug discovery by targeting cancer cells with specific genetic defects, such as BRCA deficiency, using PARP inhibitors. This approach aims to selectively kill cancer cells while sparing normal cells, improving therapeutic outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Current cancer therapies like chemotherapy and radiation have toxic side effects and limited therapeutic windows.
- Identifying drugs that selectively target cancer cells over normal cells is a major challenge in cancer drug discovery.
- Synthetic lethality has emerged as a promising strategy to address this challenge.
Purpose of the Study:
- To review the molecular mechanisms underlying synthetic lethality in cancer.
- To discuss the clinical applications of PARP inhibitors, a key example of synthetic lethality.
- To explore the methodologies, progress, advantages, and challenges of synthetic lethal screens in cancer drug discovery.
Main Methods:
- Review of molecular mechanisms of synthetic lethality.
- Analysis of clinical applications and progress of PARP inhibitors.
- Discussion of various formats and utilization of synthetic lethal screens.
Main Results:
- Synthetic lethality, exemplified by PARP inhibition in BRCA-deficient cancers, demonstrates selective killing of cancer cells.
- PARP inhibitors are advanced clinical agents targeting DNA repair mechanisms.
- Synthetic lethal screens provide a platform for identifying novel cancer-targeting agents.
Conclusions:
- Synthetic lethality represents a significant advancement in cancer therapy, offering targeted treatment strategies.
- PARP inhibitors showcase the clinical success of targeting DNA repair pathways via synthetic lethality.
- Further development and application of synthetic lethal screens are crucial for future cancer drug discovery.
